Novartis stock heads into the open after a modest gain on SIX
Published on 09/18/2026 at 08:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock closed at CHF 114.90 on the SIX Swiss Exchange on September 17, 2026, marking a gain of about 0.6% for the session per exchange data. Compared with the Swiss Market Index, which advanced more strongly on the same day, the shares underperformed the broader Swiss equity benchmark.
September 17, 2026 in numbers
Novartis AG (ISIN CH0012005267) saw its shares trade between roughly CHF 114.50 and CHF 115.40 on SIX SX on September 17, 2026, with the closing price of CHF 114.90 sitting near the middle of that intraday range according to intraday market data. Per trading statistics from the Swiss venue, daily turnover remained within the stock's recent average, signaling neither unusually heavy nor unusually light participation in the last session. A same-day wrap from the German portal IT BOLTWISE noted that Novartis also closed slightly lower on Xetra on September 17, 2026 and trailed the friendlier tone of the wider German market. In the context of the week, the CHF 114.90 finish left the stock a few percent below recent highs, underscoring a restrained reaction to ongoing news flow.
Pipeline setbacks and today's focus
Recent coverage from Yahoo Finance highlighted that Novartis has suffered several drug trial setbacks in close succession, including a failure in the del-desiran program that triggered a double-digit percent single-day share drop earlier in the week. As ad-hoc-news reported on September 17, 2026, the stock continued to trade in the CHF 114 to CHF 115 area after an ALS study failure, while analysts such as UBS maintained a neutral rating. Today, investors are set to watch for any further company statements or analyst commentary on the recent clinical data, as well as broader healthcare sector moves, which could influence Novartis shares when the next SIX SX session gets under way.
